Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β2

Molecular Carcinogenesis

Volumn 54, Issue 9, 2015, Pages 730-741

  Ting, Harold J ^a   Deep, Gagan ^a,b   Jain, Anil K ^a   Cimic, Adela ^c   Sirintrapun, Joseph ^c   Romero, Lina M ^d   Cramer, Scott D ^b,d   Agarwal, Chapla ^a,b   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Cancer associated fibroblast; Chemoprevention; Prostate cancer; Silibinin; Tumor microenvironment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; SILIBININ; TRANSFORMING GROWTH FACTOR BETA2; VIMENTIN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; SILYMARIN;

ARTICLE; CANCER ASSOCIATED FIBROBLAST; CELL DEATH; CELL DIFFERENTIATION; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFICACY; FIBROBLAST; HUMAN; HUMAN CELL; LNCAP CELL LINE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROSTATE STROMAL CELL; PROTEIN EXPRESSION; PROTEIN TARGETING; STROMA CELL; UPREGULATION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; SILYBUM MARIANUM; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; FIBROBLASTS; HUMANS; MALE; MILK THISTLE; PROSTATE; PROSTATIC NEOPLASMS; SILYMARIN; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84925663696     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22135     Document Type: Article

References (46)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625-1638.
2. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030-3044.
3. Belpomme D, Irigaray P, Hardell L, et al. The multitude and diversity of environmental carcinogens. Environ Res 2007; 105:414-429.
4. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343:78-85.
5. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis 2000; 21:379-385.
6. Mucci LA, Wedren S, Tamimi RM, Trichopoulos D, Adami HO. The role of gene-environment interaction in the aetiology of human cancer: Examples from cancers of the large bowel, lung and breast. J Intern Med 2001; 249:477-493.
7. Irigaray P, Newby JA, Clapp R, et al. Lifestyle-related factors and environmental agents causing cancer: An overview. Biomed Pharmacother 2007; 61:640-658.
8. Willett WC. Diet cancer. Oncologist 2000; 5:393-404.
9. Rodriguez C, McCullough ML, Mondul AM, et al. Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2006; 15:211-216.
10. Li H, Fan X, Houghton J. Tumor microenvironment: The role of the tumor stroma in cancer. J Cell Biochem 2007; 101:805-815.
11. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1:119-150.
12. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15:97-101.
13. Barclay WW, Woodruff RD, Hall MC, Cramer SD. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology 2005; 146:13-18.
14. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59:5002-5011.
15. Deep G, Agarwal R. Targeting tumor micro environment with silibinin: Promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets 2013; 13:486-499.
16. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
17. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
18. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: How localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009; 27:3916-3922.
19. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 2000; 283:354-360.
20. Giannoni E, Bianchini F, Masieri L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010; 70:6945-6956.
21. Santibanez JF, Quintanilla M, Bernabeu C. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2011; 121:233-251.
22. Ikushima H, Miyazono K. TGF-beta signal transduction spreading to a wider field: A broad variety of mechanisms for context-dependent effects of TGF-beta. Cell Tissue Res 2012; 347:37-49.
23. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6:506-520.
24. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006; 124:491-504.
25. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 2002; 21:1759-1767.
26. Agarwal C, Tyagi A, Kaur M, Agarwal R. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 2007; 28:1463-1470.
27. Tyagi A, Sharma Y, Agarwal C, Agarwal R. Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells. Pharm Res 2008; 25:2143-2150.
28. Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate 2002; 53:211-217.
29. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003; 12:933-939.
30. Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) 2011; 4:1222-1232.
31. Wu K, Zeng J, Li L, et al. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol Rep 2010; 23:1545-1552.
32. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008; 68:6822-6830.
33. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: Induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res 1998; 4:1055-1064.
34. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 2007; 28:2567-2574.
35. Deep G, Raina K, Singh RP, Oberlies NH, Kroll DJ, Agarwal R. Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: Comparison with silymarin and silibinin. Int J Cancer 2008; 123:2750-2758.
36. Bremnes RM, Donnem T, Al-Saad S, et al. The role of tumor stroma in cancer progression and prognosis: Emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011; 6:209-217.
37. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-444.
38. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7:256-269.
39. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: The evidence. Histopathology 2012; 60:199-215.
40. Hinz B, Mastrangelo D, Iselin CE, Chaponnier C, Gabbiani G. Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am J Pathol 2001; 159:1009-1020.
41. Grinnell F. Fibroblasts myofibroblasts, and wound contraction. J Cell Biol 1994; 124:401-404.
42. Andreassen CN, Alsner J, Overgaard J, et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 2005; 75:18-21.
43. Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:759-764.
44. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006; 29:305-314.
45. Chen YH, Liang CM, Chen CL, et al. Silibinin inhibits myofibroblast transdifferentiation in human tenon fibroblasts and reduces fibrosis in a rabbit trabeculectomy model. Acta Ophthalmol 2013; 91:e506-e515.
46. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007; 25:139-146.